Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2024-2032
비흑색종 피부암 치료(NMSC, Non-Melanoma Skin Cancer Treatment) 시장 규모는 2023년 5억 6,320만 달러에 달했습니다. IMARC 그룹은 향후 시장이 2032년까지 8억 5,010만 달러에 달할 것으로 예상했으며, 2024년과 2032년 사이에 4.5%의 성장률(CAGR)을 보일 것으로 예측했습니다.
비흑색종 피부암(NMSC)은 피부의 상층부에서 악성 세포의 이상 증식을 말합니다. NMSC의 일반적인 유형으로는 기저세포암, 머클세포암, 편평상피암, 피부 T세포 림프종 등이 있습니다. 주로 피부에 딱딱한 먼지와 비늘 모양의 반점이 생기는 것이 특징입니다. 치료 수법으로는 현미경 수술, 레이저 치료, 동결 요법 등의 외과적 처치에 의한 암세포의 제거나 광선역학적 요법(PDT), 방사선치료, 전기치료 등 다양한 비수술적 치료가 있습니다.
피부암의 유병률 증가와 세계 노인 인구 증가가 시장 성장을 가속하는 주요 요인이 되고 있습니다. 또한, NMSC에 대한 이용가능한 대체 치료법에 대한 대중의 의식 증가도 시장 성장을 자극하고 있습니다. 전통적으로 사용되는 치료법과 비교할 때, 표재성 방사선 요법은 환자의 신체에 부작용이 적고 혁신적인 휴대용 장비를 사용하여 수행 할 수 있습니다. 또한 이러한 장비는 높은 정확도와 감도로 피부 병변의 조기 진단에도 사용됩니다. 또한 전자브랙세라피(eBx)의 개발 등 다양한 기술 진보도 성장을 가속하는 요인으로 작용하고 있습니다. eBx는 통증이 없는 비침습적인 표적 저에너지 방사선 요법이며, 치료 기간이 짧고, 이웃 건강한 조직에 대한 방사선 노출의 위험을 최소화할 수 있습니다. 그 밖의 요인으로는 개인의 헬스케어 지출 증가, 임상시험에 대한 정부의 자금 지원, 광범위한 연구개발(R&D) 활동 등이 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 세계의 비흑색종 피부암 치료 시장은 지금까지 어떻게 추이했으며, 향후 어떻게 추이해 나갈 것인가?
- COVID-19는 세계의 비흑색종 피부암 치료 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 치료 유형별 시장 분석은?
- 적응증별 시장 분석은?
- 최종 용도에 따른 시장 분석은?
- 산업 밸류체인의 다양한 단계란?
- 산업의 주요 촉진요인 및 도전은 무엇인가?
- 세계의 비흑색종 피부암 치료 시장의 구조 및 주요 기업은?
- 산업 경쟁도는?
목차
제1장 서문
제2장 조사 범위 및 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 비흑색종 피부암 치료 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 치료 유형별
제7장 시장 분석 : 적응증별
제8장 시장 내역 : 최종 용도별
제9장 시장 분석 : 지역별
- 북미
- 아시아 태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 남미
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Accuray Incorporated
- Almirall SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Elekta AB
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Icad Inc.
- Merck & Co. Inc.
- Novartis AG
- Sun Pharmaceutical Industries Limited
- Varian Medical Systems Inc.
LYJ
The global non-melanoma skin cancer treatment market size reached US$ 563.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 850.1 Million by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.
Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.
The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global non-melanoma skin cancer treatment market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on treatment type, indication and end use.
Breakup by Treatment Type:
Chemotherapy
Radiation Therapy
Photodynamic Therapy
Others
Breakup by Indication:
Basal Cell Carcinoma
T-Cell Lymphoma
Squamous Cell Carcinoma
Others
Breakup by End Use:
Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Others
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.
Key Questions Answered in This Report:
- How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the end use?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Non-Melanoma Skin Cancer Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Treatment Type
- 6.1 Chemotherapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Radiation Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Photodynamic Therapy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Indication
- 7.1 Basal Cell Carcinoma
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 T-Cell Lymphoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Squamous Cell Carcinoma
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End Use
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ambulatory Surgery Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Accuray Incorporated
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Almirall S.A.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Boehringer Ingelheim GmbH
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Elekta AB
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Eli Lilly and Company
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 F. Hoffmann-La Roche AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
- 14.3.8 Icad Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Merck & Co. Inc.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Novartis AG
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Sun Pharmaceutical Industries Limited
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Varian Medical Systems Inc.
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
